title: Treatment of childhood lymphangiomas with interferon-alpha.
abstract: OBJECTIVE
  Nonsurgical treatment of lymphangiomas has shown limited efficacy and often carries unacceptable toxicities, demonstrating the need for a more effective, less toxic therapy.
  
  
  METHODS
  We describe two patients with lymphangiomatosis treated for 12 to 40 months with recombinant interferon-alpha.
  
  
  RESULTS
  Both patients demonstrated stabilization or marked improvement of disease, based on clinical and radiologic findings, with minimal toxicity.
  
  
  CONCLUSIONS
  The favorable responses to interferon-alpha therapy in these two cases suggest that this is an effective and well-tolerated treatment for lymphangiomas in children.
authors.affiliation: Department of Pediatrics, University of Minnesota Hospitals and Clinics, Minneapolis, USA.
authors.forename: M A
authors.initials: MA
authors.lastname: Reinhardt
authors.forename: S C
authors.initials: SC
authors.lastname: Nelson
authors.forename: S F
authors.initials: SF
authors.lastname: Sencer
authors.forename: B C
authors.initials: BC
authors.lastname: Bostrom
authors.forename: S C
authors.initials: SC
authors.lastname: Kurachek
authors.forename: M E
authors.initials: ME
authors.lastname: Nesbit
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000628:therapy; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D008202:Lymphangioma / Q000628:therapy*; D008297:Male; D009378:Neoplasms, Multiple Primary / Q000628:therapy; D011994:Recombinant Proteins; D013160:Splenic Neoplasms / Q000628:therapy; D013899:Thoracic Neoplasms / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents; D007370:Interferon Type I; D011994:Recombinant Proteins